NRAS and hepatocellular carcinoma: For instance, SHP099, an antagonist targeting Src homology 2 domain-containing phosphatase 2 (SHP2), induces a senescence program in sorafenib-resistant HCC cell lines, leading to vulnerability reacquisition of cancer cells to sorafenib in HCC xenografts and survival extension in a sorafenib-refractory immune-competent mouse model with Nras/Akt-induced HCC when being combined with Sorafenib [130].